Clinical Observation Of Peitu Shumu Method In The Treatment Of Nausea And Vomiting After TACE For Primary Hepatic Carcinoma

Objective:To investigate the clinical efficacy of Peitu Shumu Method(Xiaoyao Powder Modified)combined with Anti-vomiting drugs on preventing and treating nausea and vomiting after transcatheter hepatic arterial chemoembolization(TACE)of primary liver cancer(liver stagnation and spleen deficiency type),and to observe the clinical efficacy and safety of Peitu Shumu Methodcombined with Anti-vomiting drugs in the treatment of nausea and vomiting after TACE of primary liver cancer,and to enrich the treatment plan for clinical liver cancer after TACE at the same time.Methods:From January 2021 to February 2022 in the Department of Hepatobiliary and Pancreatic Surgery of Xiamen Traditional Chinese Medicine Hospital,72 patients with nausea and vomiting after hepatic arterial chemoembolization for primary liver cancer who met the inclusion criteria were screened as a study.The subjects were divided into observation group and control group according to the random number method,with 36 cases in each group.On the basis of general treatments such as liver protection,immunity enhancement and antiviral treatment,they were treated differently: the control group received postoperative routine treatment.Western medicine was used for symptomatic and supportive treatment.If there was vomiting of grade Ⅲor above,metoclopramide injection 10 mg/time intramuscular injection was used;the treatment group was treated with Peitu and Shumu method on the basis of the treatment of the control group,and both groups were observed for 7 days.Efficacy evaluation of nausea and vomiting,TCM syndrome score,Karnofsky Performance Status(KPS)score,quality of life score,changes in BMI were used respectively,and t test,chi-square test and nonparametric test were used.analyzed by statistical methods.Results: The observation group was enrolled in 36 cases and completed 36 cases,while the control group was enrolled in the group with 36 cases and completed in 36 cases.1.Efficacy evaluation of nausea and vomiting: After treatment,there was a statistically significant difference in the grades of nausea and vomiting between the two groups(P<0.05),and the grades in the control group were significantly higher than those in the observation group.There were statistically significant differences in nausea and vomiting indexes between the two groups before and after the experiment(P=0.000<0.05),and the grades before treatment were significantly higher than those after treatment.2.TCM syndrome score: Comparison between groups,before treatment between two groups The difference was not statistically significant(P>0.05),and the difference was statistically significant after treatment(P<0.05).The TCM syndrome scores of the observation group were significantly decreased.3.Comparison of KPS score: There was a statistically significant difference in KPS score between the two groups after treatment(P<0.05).4.Comparison of QOL quality of life scores: after treatment,the difference between the two groups was statistically significant(P<0.05),and the observation group was significantly higher than the control group.5.BMI comparison: There was a statistically significant difference in the efficacy evaluation of BMI between the two groups(P<0.05),and the percentage of people who decreased in the control group was significantly higher than that in the observation groupConclusion: Peitu Shumu Method(Xiaoyao Powder Modified)combined with antiemetics in the treatment of nausea and vomiting after hepatic arterial chemoembolization for primary liver cancer(liver stagnation and spleen deficiency type)is more effective than antiemetics alone,not only can effectively relieve its symptoms,also improve their quality of life.